Celldex Therapeutics, Inc. (NASDAQ:CLDX), announced that several clinical programs, including the Phase 2 ReACT study of RINTEGA® (rindopepimut) in patients with recurrent glioblastoma (GBM), will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
The ReACT presentation will include final analysis of progression-free survival at 6 months (PFS6) and current data on overall survival and other endpoints. Data contained in the published abstract were from an analysis in October 2014. Data to be presented in the oral session will include comprehensive data from the study through March 2015.
- Abstract #2009: Data from the ReACT study will be presented by David A. Reardon, M.D., in an oral presentation entitled “ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma” on Sunday, May 31, 2015 at 8:00 a.m. CDT. Dr. Reardon, Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Center; Associate Professor of Medicine, Harvard Medical School; and President of the Society for Neuro-Oncology, as well as the lead investigator of the ReACT study, will speak during the Clinical Science Symposium “Immunotherapy for Central Nervous System Tumors: Biomarkers and Novel Data.”
- Abstract #TPS1110: The Phase 2b METRIC study will be presented in a clinical trial in progress session as a poster entitled “METRIC: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC)” on Saturday, May 30, 2015 from 8:00 a.m. to 11:30 a.m.
- Abstract #TPS3105: Data from an investigator-sponsored, Phase 1/2 study of CDX-301, a potent hematopoietic cytokine that stimulates the expansion and differentiation of hematopoietic stem cells and dendritic cells, will be presented as a poster entitled “In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy” on Saturday, May 30, 2015 from 8:00 a.m. to 11:30 a.m. (Original Source)
Shares of Celldex Therapeutics closed today at $26.1, up $0.23 or 0.89%. CLDX has a 1-year high of $32.82 and a 1-year low of $11.93. The stock’s 50-day moving average is $26.77 and its 200-day moving average is $22.34.
On the ratings front, Celldex has been the subject of a number of recent research reports. In a report issued on April 30, Cantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating on CLDX, with a price target of $38, which represents a potential upside of 46.0% from where the stock is currently trading. Separately, on April 29, Brean Murray Carret’s Jonathan Aschoff reiterated a Buy rating on the stock and has a price target of $35.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Mara Goldstein and Jonathan Aschoff have a total average return of 12.1% and 6.6% respectively. Goldstein has a success rate of 56.3% and is ranked #503 out of 3600 analysts, while Aschoff has a success rate of 52.6% and is ranked #525.
The street is mostly Bullish on CLDX stock. Out of 5 analysts who cover the stock, 5 suggest a Buy rating . The 12-month average price target assigned to the stock is $36.20, which implies an upside of 39.1% from current levels.
Celldex Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the development, manufacturing and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.